^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GT201

    i
    Other names: GT201, Autologous tumor infiltrating lymphocyte injection, GT 201
    Associations

    News

    Trials
    Company:
    Grit Biotechnology
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    10ms
    Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (clinicaltrials.gov)
    P1, N=26, Recruiting, Grit Biotechnology
    New P1 trial
    |
    GT201
    10ms
    Clinical Study of GT201 in Combination with PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=12, Recruiting, Grit Biotechnology | N=32 --> 12
    Enrollment change
    |
    GT201
    10ms
    Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Grit Biotechnology | N=16 --> 40
    Enrollment change
    |
    GT201
    10ms
    Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=42, Recruiting, Grit Biotechnology | Phase classification: P1 --> P1/2 | N=26 --> 42
    Phase classification • Enrollment change
    |
    GT201
    over1year
    Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P=N/A, N=16, Recruiting, Grit Biotechnology
    New trial • Metastases
    |
    GT201
    over1year
    Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=32, Recruiting, Grit Biotechnology | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    GT201
    over1year
    Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, Grit Biotechnology | Trial completion date: Jan 2027 --> Apr 2027 | Initiation date: Jan 2024 --> Apr 2024 | Trial primary completion date: Jan 2027 --> Apr 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    GT201
    almost2years
    GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Grit Biotechnology | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    GT201
    almost2years
    Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, Grit Biotechnology | N=20 --> 32
    Enrollment change • Combination therapy • Metastases
    |
    GT201
    almost2years
    Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer) (clinicaltrials.gov)
    P=N/A, N=26, Recruiting, Grit Biotechnology
    New trial • Metastases
    |
    GT201
    almost2years
    Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, Grit Biotechnology
    New trial • Combination therapy • Metastases
    |
    GT201
    2years
    GT201 Injection For The Treatment Of Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=18, Recruiting, Grit Biotechnology
    New P1/2 trial • Metastases
    |
    GT201